Hirulog in the treatment of unstable angina: Results of the thrombin inhibition in myocardial ischemia (TIMI) 7 trial

Circulation

Volumn 92, Issue 4, 1995, Pages 727-733

  Fuchs, Joanna ^a   Cannon, Christopher P ^a   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

angina; anticoagulants; Hirulog

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; HEPARIN; HIRULOG; NITRATE; THROMBIN INHIBITOR;

ADULT; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0029148676     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.92.4.727     Document Type: Article

References (39)

1. Davies MJ, Thomas A. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina, Br Heart J. 1985;53:363-373.
2. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-989.
3. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Circulation. 1985;71:699-708.
4. Ambrose JA, Winters SL, Arora RR, Eng A, Riccio A, Gorlin R, Fuster V. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol. 1986;7:472-478.
5. Sherman CT, Litvack F, Grundfest W, Lee M, Hickey A, Chaux A, Lass R, Kass R, Blance C, Martoff J, Morgenstern L, Ganz W, Swan HJC, Forrester J. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med. 1986;315:913-919.
6. Mandelkorn JB, Wolf NM, Surender S, Schechter JA, Kersh RI, Rodgers DM, Workman MB, Bentivoglio LG, LaPorte SM, Meister SG. lntracoronary thrombus in non-transmural myocardial infarction and in unstable angina. Am J Cardiol. 1983;52:1-6.
7. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chcsebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation. 1988;77:1213-1220.
8. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB trial. Circulation. 1994;89:1545-1556.
9. Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med. 1983;309:396-403.
10. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG, Sackett DL, Sealey BJ, Tanser PH. Aspirin, sulflnpyrazone, or both in unstable angina. N Engl J Med. 1985;313:1369-1375.
11. Theroux P, Ouimet H, McCans J, Latour J-G, Joly G, Levy G, Pelletier E, Juneau M, Stasiak J, deGuise P, Pelletier GB, Rinzler D, Waters DD. Aspirin, heparin or both to treat unstable angina. N Engl J Med. 1988;319:1105-1111.
12. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827-830.
13. Wood P. Acute and subacute coronary insufficiency. Br J Med. 1961;1:1779-1782.
14. Tedford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet. 1981;1:1225-1228.
15. Williams DO, Kirby MG, McPhearson K, Phear DN. Anticoagulant treatment in unstable angina. Br J Clin Pract. 1986;40:114-116.
16. Neri Serneri GG, Gensini GF, Poggesi L, Trotta F, Modesti PA, Boddi M, leri A, Margheri M, Casolo GC, Bini M, Rostagno C, Carnovali M, Abatte R. Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina. Lancet. 1990;335:615-618.
17. Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation. 1993;88:2045-2048.
18. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
19. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574.
20. Maraganore JM, Bourdon P, Adelman B, Cannon CP, Theroux P. Heparin variability and resistance: comparisons with a direct thrombin inhibitor. Circulation. 1992;86(suppl I):I-386. Abstract.
21. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry. 1990;29: 7095-7101.
22. Kelly AB, Maraganore JM, Bourdon P, Hanson SR, Harker LA. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin. Proc Natl Acad Sci U S A. 1992;89: 6040-6044.
23. Cadroy Y, Maraganore JM, Hanson SR, Harker LA. Selective inhibition by a synthetic hirudin peptide of fibrin-dependent thrombosis in baboons. Proc Natl Acad Sci USA. 1991;88: 1177-1191.
24. Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E, Hanson D, Mant T, Wagner J, Maraganore J. Anticoagulant activity of Hirulog™, a direct thrombin inhibitor, in humans. Thromb Haemost. 1993;69:157-163.
25. Sharma GVRK, Lapsey D, Vita JA, Sharma S, Coccio E, Adelman B, Loscalzo J. Usefulness and tolerability of Hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am J Cardiol. 1993; 72:1357-1360.
26. Lidon R-M, Theroux P, Juneau M, Adelman B, Maraganore J. Initial experience with a direct antithrombin, Hirulog, in unstable angina: anticoagulant, antithrombotic, and clinical effects. Circulation. 1993;88:1495-1501.
27. Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, Selwyn AP, Adelman B, Fox I, Braunwald E, Ganz P. Anticoagulant effects of Hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol. 1993;71: 778-782.
28. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, de Bono D, Ferguson J, Willerson JT, Strony J, Ganz P, Cohen MD, Raymand R, Fox I, Maraganore J, Adelman B. Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty. Circulation. 1993;87:1622-1629.
29. Braunwald E, Jones RH, Mark DB, Brown J, Brown L, Cheitlin MD, Concannon CA, Cowan M, Edwards C, Fuster V, Goldman L, Green LA, Grines CL, Lytle BW, McCauley KM, Mushlin AI, Rose GC, Smith EE III, Swain JA, Topol EJ, Willerson JT. Diagnosing and managing unstable angina. Circulation. 1994;90:613-622.
30. Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold HK, Tannenbaum MA, Rao AK, Debowey D, Schwartz D, Henis M, Chesebro J. Recombinant hirudin for unstable angina pectoris: a multicenter, randomized angiographic trial. Circulation. 1994;89:1557-1566.
31. Cannon CP. Hirulog. In: Messerli FH, ed. Cardiovascular Drug Therapy. Philadelphia, Pa: WB Saunders Co. In press.
32. Maraganore JM, Chao B, Joseph ML, Jablonski J, Ramachandran KL. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem. 1989;264:8692-8698.
33. Ofosu FA, Fenton JW, Maraganore J, Blajchman MA, Yang X, Smith L, Anvari N, Buchanan MR, Hirsh J. Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin. Biochem J. 1992;283:893-897.
34. Maraganore JM, Chao BH, Weitz JI, Hirsh J. Comparison of antithrombin activities of heparin and hirulog-1: basis for improved antithrombotic properties of direct thrombin inhibitors. Thromb Haemost. 1991;63:829. Abstract.
35. Maraganore JM. Pre-clinical and clinical studies on hirulog: a potent and specific direct thrombin inhibitor. In: Claeson G, Scully MF, Kakkar VV, Deadman J, eds. Design of Synthetic Inhibitors of Thrombin. New York, NY: Plenum Press; 1993:227-236.
36. Cannon CP, McCabe CH, Henry TD, Schweiger M, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E, for the TIMI 5 Investigators. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol. 1994;23:993-1003.
37. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, Pasotti C, Rudelli G, and the Studio della Ticlopidina nell'Angina Instabile Group. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. Circulation. 1990;82:17-26.
38. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, Fox KAA, Chesebro JH, Strain J, Keller C, Kelly A, Lancaster G, Ali J, Kronmal R, Fuster V, and the Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS trial. Circulation. 1994;89:81-88.
39. Cohen M, Adams PC, Hawkins L, Bach M, Fuster V. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Research Group). Am J Cardiol. 1990;66:1287-1292.